Search

Displaying results 1511 - 1520 of 4859 in total
  1. Drug

    Pyruvic acid

    go.drugbank.com/drugs/DB00119
    ApprovedInvestigationalNutraceutical

    In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed)

  2. Drug

    Human cytomegalovirus immune globulin

    go.drugbank.com/drugs/DB13886
    ApprovedInvestigational

    It contains purified immunoglobulin G (IgG) antibodies targeting cytomegalovirus (CMV)[FDA label]. … As a consequence, CMV disease is restricted to the immunocompromised or immunologically immature host, in which it can lead the devastating result of transplant rejection [A32498], [L2229].

  3. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    It was originally approved by the U.S.

  4. Drug

    Pancrelipase amylase

    go.drugbank.com/drugs/DB11065
    ApprovedInvestigational

    Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The amylases are enzymes that help in the chemical proce...

    Mixtures: Pancrease Mt 4, Pancrease Mt 16
  5. Drug

    Sulpiride

    go.drugbank.com/drugs/DB00391
    ApprovedWithdrawn

    [A229683] Sulpiride is not approved by the FDA, Health Canada, or the EMA; though it is approved in individual European countries.[L24679]

  6. Drug

    Acoramidis

    go.drugbank.com/drugs/DB17999
    ApprovedInvestigational

    [A264808] It was brought to market by BridgeBio Pharma and approved by the FDA in November 2024 to reduce negative cardiovascular outcomes in patients with cardiomyopathy caused by TTR amyloidosis.

  7. Drug

    Bleomycin

    go.drugbank.com/drugs/DB00290
    ApprovedInvestigational

    It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.

  8. Drug

    Sunitinib

    go.drugbank.com/drugs/DB01268
    ApprovedInvestigational

    Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.

  9. Drug

    Dexrazoxane

    go.drugbank.com/drugs/DB00380
    ApprovedInvestigationalWithdrawn

    It appears to inhibit formation of a toxic iron-anthracycline complex.

  10. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    [L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … It is used to manage inflammation and immune dysregulation in patients with Duchenne muscular dystrophy (DMD), a neuromuscular disorder characterized by the insidious regression of neuromuscular function